COX-3 the enzyme and the concept: steps towards highly specialized pathways and precision therapeutics?

[1]  Song‐Pyo Hong,et al.  Novel Docosanoids Inhibit Brain Ischemia-Reperfusion-mediated Leukocyte Infiltration and Pro-inflammatory Gene Expression* , 2003, Journal of Biological Chemistry.

[2]  C. Serhan,et al.  Novel Docosatrienes and 17S-Resolvins Generated from Docosahexaenoic Acid in Murine Brain, Human Blood, and Glial Cells , 2003, The Journal of Biological Chemistry.

[3]  J. Schwab,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[4]  J. Trzăskos,et al.  COX-3: in the wrong frame in mind. , 2003, Immunology letters.

[5]  R. Flower,et al.  Medicine: Lipid signals in pain control , 2002, Nature.

[6]  K. Senior.  Homing in on COX-3—the elusive target of paracetamol , 2002, The Lancet Neurology.

[7]  A. Smith.  Analgesics: Time for a new COX? , 2002, Nature Reviews Drug Discovery.

[8]  C. Serhan,et al.  Resolvins , 2002, The Journal of experimental medicine.

[9]  J. Mitchell,et al.  Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum? , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  N. V. Chandrasekharan,et al.  COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Butcher.  Blood test to detect Alzheimer's developed , 2002, The Lancet Neurology.

[12]  R. Phipps,et al.  Prostaglandins as modulators of immunity. , 2002, Trends in immunology.

[13]  L. Spain,et al.  The COX-2 inhibitor NS-398 causes T-cell developmental disruptions independent of COX-2 enzyme inhibition. , 2001, Cellular immunology.

[14]  Charles N. Serhan,et al.  Lipid mediator class switching during acute inflammation: signals in resolution , 2001, Nature Immunology.

[15]  S. Laufer,et al.  Structural approaches to explain the selectivity of COX-2 inhibitors: is there a common pharmacophore? , 2000, Current medicinal chemistry.

[16]  R. Botting,et al.  Mechanism of action of acetaminophen: is there a cyclooxygenase 3? , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  R. Matasić,et al.  Cyclooxygenase‐independent inhibition of dendritic cell maturation by aspirin , 2000, Immunology.

[18]  P. Colville-Nash,et al.  COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease , 2000, The Lancet.

[19]  R. Garavito,et al.  Cyclooxygenases: structural, cellular, and molecular biology. , 2000, Annual review of biochemistry.

[20]  O. Laneuville,et al.  Characterization of a novel transcript of prostaglandin endoperoxide H synthase 1 with a tissue-specific profile of expression. , 1999, The Biochemical journal.

[21]  L. Spain,et al.  Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. , 1999, The Journal of clinical investigation.

[22]  J. Vane,et al.  Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  N. Ueda,et al.  Transcriptional regulation of fatty acid cyclooxygenases-1 and -2. , 1998, International journal of tissue reactions.

[24]  T. Hla,et al.  Molecular characterization of the 5.2 KB isoform of the human cyclooxygenase-1 transcript. , 1996, Prostaglandins.

[25]  K. Resch,et al.  Differentiation‐associated expression of prostaglandin G/H synthase in monocytic cells , 1993, FEBS letters.